RLYB332

RLYB332 is a fully-humanized, long-acting monoclonal antibody that targets matriptase-2 (also known as TMPRSS6 or MTP-2). By inhibiting matriptase-2, RLYB332 increases levels of hepcidin, a key protein regulator of iron homeostasis in the body. This mechanism is designed to reduce serum iron and transferrin saturation, making it a potential best-in-class therapy for diseases characterized by iron overload and ineffective erythropoiesis. Preclinical data have demonstrated that RLYB332 has superior pharmacodynamic effects compared to comparator molecules on parameters such as serum iron, unsaturated iron binding capacity (UIBC), and transferrin saturation (TSAT). The drug is being developed for conditions including hereditary hemochromatosis, polycythemia vera, myelodysplastic syndrome, beta thalassemia, sickle cell anemia, and potentially other disorders where excess iron accumulation causes morbidity[1][4][5][6].

Other names

RLYB-332RLYB332RLYB 332